Trends and disparities in lung cancer and respiratory failure mortality in the US: A 24-year retrospective study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Treatment paradigms remain unclear for immune-related adverse events associated with cancer checkpoint inhibitor therapies, ...

Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy. HealthDay News — Patients with cancer aged 65 years and older receiving immune ...

Immune-related pruritus may be observed in a quarter of patients with metastatic melanoma treated with immune checkpoint ...

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung ...

Use of immune checkpoint inhibitors for cancer was associated with a significant reduction in actinic keratoses in a small study. The effect was greatest in younger patients and those with a history ...

Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti–cytotoxic T-lymphocyte–associated protein 4) + nivolumab (anti–PD-1) in untreated, metastatic melanoma has achieved a ...

The time of day that intravenous immune checkpoint inhibitor therapy is administered is unlikely to significantly affect OS in NSCLC patients.

Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.

MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...

Checkpoint inhibitor-based therapy and ISRT may replace autologous transplant and high-dose chemotherapy in low-risk relapsed cHL, reducing side effects while maintaining EFS outcomes. The CheckMate ...